⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 20, 2024Annals of the Rheumatic DiseasesOpen Access

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial

Laure Gossec Laura C. Coates Dafna D. Gladman Jacob Aelion Jitendra Vasandani Andreas Pinter Joseph F. Merola Arthur Kavanaugh Jyotsna Reddy Rebecca Wang Michèle Brunori Yuri M. Klyachkin Cynthia Deignan Philip J. Mease

View Full Paper

Ask AI

Bookmark

Share

Abstract

Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gossec et al. (2024) studied this question.

synapsesocial.com/papers/68e5b8a1b6db643587551283 https://doi.org/10.1136/ard-2024-225833

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOSTOriginal Research · 2026
2Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial2024
3Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS studyOriginal Research · 2026
4Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study2024 · 5 citations
5Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study2024 · 5 citations